Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in a Phase 1 Expansion Trial of SIRPα Antagonist Monoclonal Antibody BI 765063, Targeting Myeloid Cells in Immuno-Oncology

Boehringer Ingelheim and OSE Immunotherapeutics SA announced a new step achieved through their collaboration under which Boehringer Ingelheim obtained exclusive rights to BI 765063, a first-in-class SIRPα inhibitor on the SIRPα/ CD47 myeloid pathway being evaluated in patients with recurrent/metastatic hepatocellular carcinoma.